1-4 of 4
Junru Liu
Close
Sort by
Journal Articles

Cytogenetic Evolution and Its Effect on Prognosis in Newly Diagnosed and Relapsed MM Patients

Yanjuan Li, Beihui Huang, Xiaozhe Li, Lifen Kuang, Meilan Chen, Junru Liu, Juan Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 12527.
https://doi.org/10.1182/blood-2022-157389
Published: 2022
Journal Articles

Favorable Inductive Remission Rate of Decitabine Combined Chemotherapy on < 60-Years of Age MDS-like AML in the First Course

Fengqi Liu, MD, Xiuzhen Tong, MD, Zhenhai Zhou, MD, Dong Zheng, MD, Hehua Wang, MD, Junru Liu, MD, Beihui Huang, MD, Chang Su, MD, Waiyi Zou, MD, Duorong Xu, MD, Juan Li, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2711.
https://doi.org/10.1182/blood-2018-99-113748
Published: 2018
Journal Articles

Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma

Jingli Gu, MD, Junru Liu, MD, Meilan Chen, PhD, Beihui Huang, MD, Juan Li, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5620.
https://doi.org/10.1182/blood-2018-99-113739
Published: 2018
Journal Articles

Bortezomib with Dexamethasone in Newly Diagnosed Patients with Primary Systemic Light Chain Amyloidosis or Multiple Myeloma-Associated AL Amyloidosis

Beihui Huang, M.D., Juan Li, MD, PhD, Junru Liu, M.D., Dong Zheng, MD, PhD, Mei Chen, M.D., Zhenhai Zhou, M.D., Duorong Xu, M.D., Waiyi Zou, M.D.
Journal: Blood
Blood (2012) 120 (21): 5036.
https://doi.org/10.1182/blood.V120.21.5036.5036
Published: 2012